Methods for the diagnosis and thetreatment of graft-versus-host disease

The invention relates to methods for the prediction and the treatment of risk of acute graft versus host disease. The inventors demonstrated that an alteration of CD73-mediated regulatory function of DP8α Tregs could contribute to the acute GvHD pathophysiology. In particular, the present invention relates to method of determining whether a subject has or is at 0 a risk of developing graft-versus-host disease (GvHD) comprising the steps of: i) determining the level of CD73 expression by DP8α TREGS in a sample obtained from the subject, ii) comparing the level determined at step i) with a predetermined reference value wherein detecting differential between the level of CD73 expression by DP8α TREGS determined at step i) and the predetermined reference value is indicative of whether a subject has or is at a risk of developing graft-versus-host disease (GvHD).

Patent Application number: European Procedure (Patents) (EPA) - 04 Nov. 2020 - 20 306 320.1
Inventors:
GODEFROY EmmanuelleCHEVALLIER PatriceALTARE FrédéricJOTEREAU Francine
Publications:
Blood. 2022; Godefroy et al. CD73-Expressing Microbiota-Reactive DP8α Regulatory T Cells Are Lacking in Acute GvHD Patients and Prevent Disease Development in a Pre-Clinical In Vivo Humanized Mouse Model of GvHD

Reference:

BIO20418-T1

    Business Developper
    contact
    Inserm Transfert
    Business Developer
    Patent filling date: null
    Rare disease: No
    Second indication: No

    You might also be interested in